雷帕霉素洗脱支架治疗多支病变冠心病患者的临床疗效分析  

The study on the clinical efficacy of rapamycin eluting stent in patients with multivessel coronary disease

作　　者：陆卫华[1] 方庆[1] 龚志刚[1] 杨捍卫[1] 程健[1] 丁世芳[1] 

机构地区：[1]南方医科大学附属广州军区武汉总医院临床医学院心内科,武汉430070

出　　处：《重庆医学》2012年第34期3603-3604,3606,共3页Chongqing medicine

摘　　要：目的研究雷帕霉素洗脱支架治疗(RES)多支病变冠心病患者的临床疗效及安全性。方法选取2004年5月至2010年5月312例多支病变冠心病患者,其中包括RES组(n=150)和普通金属支架治疗组(BMS组,n=162)。随访两组患者的相关临床资料情况。结果 BMS组的主要不良心脏事件总发生率为17.28%,而RES组的主要不良心脏事件总发生率为5.33%,明显低于BMS组(P<0.05),同时,RES组的冠状动脉造影复查再狭窄发生率较BMS组明显低(P<0.05);BMS组的心功能改善率为29.63%,而RES组的心功能改善率为63.33%,明显高于BMS组(P<0.05)。结论 RES多支病变冠心病患者既安全又可靠,明显改善心功能,主要不良心脏事件发生率显著降低,同时具有较低的再狭窄发生率。Objective To analysis the clinical efficacy and safety of Rapamycin eluting stent in patients with multivessel coronary disease. Methods 312 patients with multivessel coronary disease were selected and divided into two groups： Rapamycin eluting stent treatment group（n=150） and bare metal stent treatment group（n= 162）. After 8 months. Then we analyze all the patientst clinical data in the two groups randomly. Results There were significant differences major adverse cardiac events overall incidence between the two groups （5.33 % vs. 17. 28%, P〈 0.05）. Meanwhile, restenosis rate of Rapamycin eluting stent treatment group were significantly lower than that of bare metal stent treatment group（1.33% vs. 6.17% ,P〈0.05）. And the improvement rate of heart function in Rapamycin eluting stent treatment group were significantly higher than that in bare metal stent treatment group （63.33% vs. 29.63% ,P〈0.05）. Conclusion This study indicates that Rapamycin eluting stent in treatment for multivessel coronary disease is safe and reliable; it can improve heart function and reduce major adverse cardiac events significantly and lower the restenosis rate.

关 键 词：冠状动脉疾病 支架 再狭窄 

分 类 号：R541.4[医药卫生—心血管疾病]